Earnings summaries and quarterly performance for Lucid Diagnostics.
Executive leadership at Lucid Diagnostics.
Board of directors at Lucid Diagnostics.
Research analysts who have asked questions during Lucid Diagnostics earnings calls.
EW
Edward Woo
Ascendiant Capital Markets
4 questions for LUCD
Also covers: AIM, AMTX, ATOS +17 more
Mark Massaro
BTIG, LLC
4 questions for LUCD
Also covers: ADPT, AKYA, BLLN +19 more
AV
Anthony Vendetti
Maxim Group
3 questions for LUCD
Also covers: AEMD, AGFY, BHST +19 more
KM
Kyle Mikson
Canaccord Genuity
3 questions for LUCD
Also covers: AKYA, BDSX, CSTL +12 more
Michael Matson
Needham & Company
3 questions for LUCD
Also covers: AORT, ATRC, CNMD +22 more
RO
Ross Osborn
Cantor Fitzgerald
2 questions for LUCD
Also covers: AXGN, CERS, CVRX +12 more
JP
Jeremy Pearlman
Analyst
1 question for LUCD
Also covers: AEMD, JYNT, NEPH +5 more
Mike Matson
Needham & Company, LLC
1 question for LUCD
Also covers: CNMD, ENOV, ESTA +16 more
Recent press releases and 8-K filings for LUCD.
Lucid Diagnostics Reports Q3 2025 Financial Results and Business Updates
LUCD
Earnings
Product Launch
New Projects/Investments
- Lucid Diagnostics reported $1.2 million in EsoGuard® Esophageal DNA Test revenue for the third quarter ended September 30, 2025, having processed 2,841 EsoGuard tests.
- For the three months ended September 30, 2025, Lucid Diagnostics' GAAP net loss attributable to common stockholders was approximately $6.3 million, or $(0.29) per diluted common share.
- Lucid Diagnostics strengthened its balance sheet by netting approximately $27.0 million from a public offering of common stock and is progressing towards transformative Medicare coverage for EsoGuard.
- PAVmed's subsidiary, Veris Health, launched the commercial phase of its strategic partnership with The Ohio State University James Cancer Hospital and relaunched development of an implantable physiological monitor. PAVmed also signed a letter of intent to license a new endoscopic esophageal imaging technology.
Nov 13, 2025, 1:00 PM
Lucid Diagnostics Reports Q3 2024 Financial and Strategic Highlights
LUCD
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Lucid Diagnostics reported record quarterly revenue of $1.2 million in Q3 2024, marking a 20% increase quarter-over-quarter, with EsoGuard test volume reaching 2,787.
- The company recorded a net loss of $12.371 million for Q3 2024.
- A significant strategic achievement was the acceptance of the ESOGUARD BE-1 clinical validation study for peer-reviewed publication, completing the clinical evidence package required for submission to formally seek Medicare coverage.
- Commercially, Lucid Diagnostics is expanding its direct contracting initiative through multiple programs aimed at driving near-term revenue.
Nov 12, 2025, 1:30 PM
LUCD Reports Q3 2025 Results, Strengthens Balance Sheet, and Advances Medicare Coverage
LUCD
Earnings
New Projects/Investments
- LUCD reported Q3 2025 revenue of $1.2 million and EsoGuard test volume of 2,841 tests, consistent with the prior quarter.
- The company secured approximately $27 million in proceeds from an underwritten public offering, bolstering its cash balance to $47.3 million at the end of Q3 2025 and extending its financial runway through 2026.
- A Medicare Contractor Advisory Committee meeting in September provided a unanimous endorsement for EsoGuard Medicare coverage, which is considered a final step towards securing coverage, with a draft local coverage determination anticipated soon.
- The Q3 2025 non-GAAP net loss per share was $0.10, remaining flat sequentially.
Nov 12, 2025, 1:30 PM
Lucid Diagnostics Reports Q3 2025 Financial Results and Business Update
LUCD
Earnings
Guidance Update
New Projects/Investments
- Lucid Diagnostics reported $1.2 million in EsoGuard revenue and a GAAP net loss of approximately $10.4 million, or $(0.10) per common share, for the three months ended September 30, 2025.
- The company processed 2,841 EsoGuard® tests in Q3 2025.
- Lucid Diagnostics ended Q3 2025 with $47.3 million in cash and cash equivalents, an increase from $22.4 million as of December 31, 2024, after netting approximately $27.0 million from a public offering, extending its cash runway through 2026.
- A Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting yielded unanimous expert consensus supporting Medicare coverage for EsoGuard, representing a key step in the final stages of the Local Coverage Determination (LCD) reconsideration process.
Nov 12, 2025, 1:15 PM
Lucid Diagnostics Reports Third Quarter 2025 Financial Results and Business Update
LUCD
Earnings
New Projects/Investments
Guidance Update
- Lucid Diagnostics processed 2,841 EsoGuard® tests and recognized $1.2 million in EsoGuard revenue for the three months ended September 30, 2025.
- The company reported a GAAP net loss of $10.4 million or $(0.10) per common share for the third quarter of 2025.
- As of September 30, 2025, Lucid Diagnostics held $47.3 million in cash and cash equivalents, boosted by approximately $27.0 million in net proceeds from a public offering, which extends its financial runway through 2026.
- A Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting resulted in unanimous expert consensus supporting Medicare coverage for EsoGuard, marking a significant step towards securing this key reimbursement milestone.
Nov 12, 2025, 1:00 PM
Lucid Diagnostics Provides Update on Esophageal Precancer Screening Solution and Reimbursement Progress
LUCD
New Projects/Investments
Revenue Acceleration/Inflection
- Lucid Diagnostics (LUCD) is advancing its EsoCheck cell collection device and EsoGuard esophageal DNA test for esophageal precancer screening, targeting an estimated ~$60 billion total addressable U.S. market with over 90% gross margin per test.
- A significant reimbursement milestone occurred on September 4, 2025, when a Multi-Jurisdictional Contractor Advisory Committee (CAC) Meeting showed strong consensus supporting nonendoscopic precancer testing using EsoGuard as part of the MoIDX Local Coverage Determination (LCD) reconsideration process. A final LCD would permit payment for claims dating back one year.
- While cumulative EsoGuard test volume reached 38,000 by 2Q25, no claims have been submitted or paid as of that period, highlighting the critical importance of the pending reimbursement decision.
- As of 2Q25, the company reported ProForma Cash of $58.1 million (including Sept CMPO) and an average quarterly burn rate of $10.5 million over the trailing four quarters.
Sep 18, 2025, 11:00 AM
Lucid Diagnostics Appoints Danielle Scelfo to Senior Vice President Role
LUCD
Management Change
Hiring
New Projects/Investments
- Lucid Diagnostics Inc. has appointed Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer.
- Ms. Scelfo will oversee market access and reimbursement activities, focusing on securing broad insurance coverage for the company's EsoGuard® Esophageal DNA Test.
- This appointment is strategic, anticipating key reimbursement milestones, including Medicare coverage for EsoGuard, and aims to accelerate commercial coverage expansion.
Sep 16, 2025, 12:01 PM
Lucid Diagnostics Announces Closing of Public Offering
LUCD
- Lucid Diagnostics Inc. (Nasdaq: LUCD) announced the closing of its previously announced underwritten public offering of common stock on September 11, 2025.
- The offering involved the sale of 28,750,000 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.00 per share.
- The company expects to receive approximately $26.9 million in total net proceeds from the offering, after deducting underwriting discounts and other estimated expenses.
- The net proceeds are intended for working capital and general corporate purposes.
Sep 11, 2025, 1:27 PM
Lucid Diagnostics Announces Closing of Public Offering
LUCD
- Lucid Diagnostics Inc. (Nasdaq: LUCD) announced the closing of its public offering of 28,750,000 shares of common stock on September 11, 2025.
- The shares were offered at a public offering price of $1.00 per share, including 3,750,000 shares issued from the full exercise of the underwriters' option to purchase additional shares.
- The total net proceeds from the offering are expected to be approximately $26.9 million.
- Lucid Diagnostics intends to use the net proceeds for working capital and general corporate purposes.
Sep 11, 2025, 1:17 PM
Lucid Diagnostics Provides Update on Medicare Coverage and Commercial Strategy
LUCD
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Lucid Diagnostics is actively pursuing Medicare coverage for its EsoCheck esophageal cancer precancer detection test, with a key meeting scheduled for September 4 as part of the MolDx reconsideration process. The company believes this process was designed to provide a roadmap for coverage once sufficient data was available.
- The company is currently performing approximately 2,500-3,000 tests per quarter, with 83% of claims denied and a 17% reimbursement rate from out-of-network commercial payers, as it awaits broader coverage.
- Lucid's operations, including manufacturing and lab capacity, are scalable to significantly higher volumes, and the company plans to actively target the Medicare patient population (which represents 40-50% of the 30 million eligible patients) once coverage is secured.
- Management anticipates securing Medicare coverage and meaningful commercial coverage within the next year, which is expected to lead to significant revenue growth and market penetration.
Aug 13, 2025, 7:45 PM
Quarterly earnings call transcripts for Lucid Diagnostics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more